Collecting blood samples from cancer patients for genetic analysis
Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications
National Institutes of Health Clinical Center (CC) · NCT01441089
This study is collecting blood samples from cancer patients to see how their genes might affect how well treatments work and what side effects they experience.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1100 (estimated) |
| Ages | 3 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) (nih) |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT01441089 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect blood or cheek swab samples from individuals undergoing cancer treatment to analyze genetic differences that may influence treatment efficacy and side effects. Participants include those with various cancers, such as prostate, breast, lung, and ovarian cancers, as well as lymphoma. The study focuses on understanding how genetic variations affect drug metabolism and response to therapy, with the goal of improving treatment outcomes and minimizing adverse effects. A total of 1,100 patients will be enrolled to provide samples for genomic analysis.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 3 years and older with cancer or tumor predisposition syndromes currently enrolled in NIH therapeutic clinical trials.
Not a fit: Patients not currently undergoing cancer treatment or those without a tumor predisposition syndrome may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized cancer treatments that reduce side effects and improve effectiveness based on genetic profiles.
How similar studies have performed: Other studies have shown promise in using genetic analysis to tailor cancer treatments, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment. * Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document. * Age \>= 3 years old EXCLUSION CRITERIA: -N/A
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: William D Figg, Pharm.D. — National Cancer Institute (NCI)
- Study coordinator: Deneise C Francis, R.N.
- Email: deneise.francis@nih.gov
- Phone: (240) 858-3974
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma, Pharmacogenetics, Pharmacokinetics, Pharmacodynamics